– UK, Cambridge – Dante Labs, a global leader in genomics and precision medicine, today announced the appointment of Mark Van Oene to its Board of Directors.
“I’m so pleased to welcome Mark Van Oene to the Dante Labs Board,” said CEO, Andrea Riposati. “We are confident we will greatly benefit from Mark’s proven leadership in scaling Dante’s global commercial organization to serve more people with the genomic information needed to treat and prevent disease.”
Mr. Van Oene will join Illumina COO Bob Ragusa and GRAIL SVP Mark Morgan to the Dante Labs Board of Directors.
About Mark Van Oene
Mark Van Oene is the COO at Pacific Biosciences, a leading provider of high-quality sequencing solutions. He has deep expertise and leadership in the field of genomics, driving strategic planning and corporate development activities and managing research, development, and manufacturing in his role at Pacific Biosciences. Before that, Mr. Van Oene held several key leadership roles at Illumina, ultimately serving as Chief Commercial Officer with his appointment in 2017. Before Illumina, he was the Director of Genotyping Services in Ellipsis Biotherapeutics.
Mr. Van Oene commented, “I’m excited to be joining Dante’s Board to help scale the business as the need for genomics in healthcare is realized and plays a more essential role in drug development and precision medicine.”
About Dante Labs
Dante Labs is a global genomic data company building and commercializing a new class of transformative health and longevity applications based on whole-genome sequencing and AI. Our assets include one of the largest private genome databases with research consent, a proprietary software platform designed to unleash the power of genomic data at scale, and proprietary processes which enable an industrial approach to genomic sequencing.
Headquartered in Cambridge, United Kingdom, with a research laboratory in Wolverhampton, Dante Labs supported the UK Government’s urgent requirement to scale up a high-capacity, highly automated testing solution for Covid-19, including infected patients as well as those with antibodies. Dante Labs was able to deliver by leveraging existing technology which had been developed for whole-genome sequencing.
For more information: https://www.dantelabs.com/
Sorry, the comment form is closed at this time.